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SHORT COMMUNICATION
Matrix heparan sulphate, but not endothelial cell surface heparan
sulphate, is degraded by highly metastatic mouse lymphoma cells
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An endoglycosidase from a highly metastatic variant (ESb)
of a low-metastatic T-cell lymphoma (Eb) has previously
been shown to degrade heparan sulphate-containing material
produced by vascular endothelial cells. Such enzyme activity
was not detected in the parental cell line Eb (Vlodavsky et
al., 1983). This supports the concept that tumour cell-
associated enzymes are necessary for the penetration of
blood vessel walls, as an early decisive step of metastasis
(Pauli et al., 1983; Kramer & Vogel, 1984; Becker et al.,
1986). We have now studied the substrate specificity of the
endoglycosidase described for the Eb/ESb tumour system on
purified proteoglycans. The experimental system described
here consisted of the murine methylcholanthrene-induced,
low metastatic T lymphoma Eb, its highly metastatic variant
ESb (Schirrmacher et al., 1979) and a low-metastatic variant
of ESb, ESb-MP, which was selected for its plastic-adherent
growth in vitro (Fogel et al., 1983). Eb and ESb cells were
distinguished from each other by their specific expression
of differentiation antigens (Altevogt et al., 1982), tumour-
associated transplantation antigens (TATA) (Schirrmacher &
Bosslet, 1982) and cell surface glycoconjugates (Schwartz et
al., 1984; 1985) whereas the variant ESb-MP is more closely
related to the cell line ESb - both cell types express identical
differentiation antigens and TATA (Fogel et al., 1983).
These three cell lines were investigated for their ability to
degrade a proteochondroitin sulphate (PCS), a cell surface
proteoheparan sulphate (HS I) from bovine aortic endo-
thelial cells which is released into the culture medium by
plasma membrane shedding (Keller et al., 1987) and a
basement membrane proteoheparan sulphate (HR9-PHS)
from HR9-cells (Keller & Furthmayr, 1986). The two major
proteoglycans from endothelial cell conditioned medium,
HS I (cell surface proteoheparan sulphate) and the low
molecular weight PCS (proteochondroitin sulphate), were
isolated by chromatography on Sepharose CL-4B (Figure la)
and, in a subsequent step, by chromatography on DEAE-
Sephacel (Figure lb). Finally, the proteoglycans were puri-
fied by CsCI density gradient ultracentrifugation (data not
shown).
The preparations obtained were characterized by alkali
degradation and by digestion with Chondroitinase AC or
Heparinase (Figure 2a-c). These purified substances were
used to coat microtitre wells.
Typically, the labelled proteoglycans were bound to the
plastic surface with 10% efficiency. The substances could be
released from the plastic surface with 7 M urea plus 2% (w/v)
SDS. No qualitative difference was observed between the
bound fractions and the proteoglycans remaining in the
supernatant. However, when proteoglycans were presented in
soluble form to the tumour cells, no degradative effect could
be observed (data not shown). This may be due to a higher
concentration of the substrate when presented in immobi-
lized form.
After incubation of the 3 tumour cell lines on proteoglycan-
coated plates no degradation of endothelial PCS or HS I by
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any of the cell lines studied was observed (Figure 2d-k).
Only HR9-PHS was degraded by ESb cells (Figure 21). We
have repeated the degradation experiments 15 times using
proteoglycan samples from 4 independent preparations. In
all of these experiments the same degradation pattern was
observed. In kinetic experiments (Figure 3) the (35S)-HR9-
PHS-coated wells were incubated with suspensions of ESb
cells for various times. There was a time dependent, gradual
shift towards labelled degradation products of lower molecu-
lar weight, which appeared at the V, of the Sepharose CL-6B
chromatography column. At no time did we observe com-
pounds of the size of the free glycosaminoglycan chain.
From these data, it is suggested that proteolytic degradation
of the proteoheparan sulphate, which would result in the
release of single peptidoglycosaminoglycans, is minor com-
pared to the digestion of the heparan sulphate polysac-
eharide portion.
The results presented here essentially confirm those of
Vlodavsky and coworkers (Vlodavsky et al., 1983; Bar-Nel et
al., 1985) who demonstrated endoglycosidase activity
released by ESb in contrast to Eb cells. These authors
proposed a sequential degradation of proteoglycans em-
bedded in the extracellular matrix, first by serine-proteases
(Kramer et al., 1985; Bar-Ner et al., 1986) producing high
molecular sulphate labelled compounds and then by an
endoglycosidase degrading these substances to low molecular
fragments. This concept does not necessarily contradict our
observation that the endoglycosidase alone is capable of the
total degradation of the HR9-PHS, because in the intact
ECM the proteoheparan sulphate may first need to be
liberated from its interaction with various proteins (Lindahl
& H66k, 1978). Proteolytic activity may thus facilitate the
accessibility of the proteoglycan for an effective endoglyco-
sidase action. Since low-metastatic Eb cells only produce the
protease, but not the endoglycosidase, it may be that due to
its size and high negative charge the proteoheparan sulphate
itself still impedes tumour cell invasion. Therefore, it seems
that the production of an ECM-proteoheparan sulphate-
specific endoglycosidase is a pivotal factor for the invasive
capacity of a tumour cell. This hypothesis is corroborated by
the absence of endoglycosidase activity in the low-metastatic,
plastic-adherent variant ESb-MP which is otherwise closely
related to the metastatic ESb cells and expresses similar
serine proteases (Schirrmacher et al., 1987). Furthermore,
since cell surface proteoheparan sulphate was not degraded,
it is likely that the tumour cell-derived endoglycosidase
activity is not involved in attachment to and penetration of
the endothelial cell layer. The different susceptibility of cell
surface- and ECM-proteoheparan sulphate to this endoglyco-
sidase may be based on the structural heterogeneity of
different species of proteoheparan sulphates (for review see
Gallagher et al., 1986).
From our results and earlier observations (Vlodavsky et
al., 1983), in which successful invasion of vascular endothe-
lium was more associated with morphological deformations
of the tumour cells rather than to enzymatic activity, we
conclude that the subendothelial ECM is the main target for
tumour-associated proteases and endoglycosidases. In addi-
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Figure 1 (a) Separation of endothelial proteoglycans on Sephar-
ose CL-4B chromatography. Medium from mass cultured bovine
aortic endothelial cells (- x 109 cells) and from 1 x 107 cells
incubated with 25 pCi (35S)-sulphateml-' for 48 h, was first
chromatographed on Sepharose CL-6B and DEAE-Sephacel
(data not shown). For separation into crude endothelial proteo-
heparan sulphate (HSI) and endothelial proteochondroitin sul-
phate (PCS), as determined by its susceptibility to heparinase or
chondroitinase AC treatment, the substance was then chromato-
graphed on Sepharose CL-4B (2 x 150cm) in 0.13 M Tris/HCI,
0.I% (w/v) SDS (sodium dodecyl sulphate), 1 mM PMSF (phenyl-
methylsulphonyl fluoride), 1 mM EDTA, pH 7.2. Fractions of
3ml were collected at 25mlh-1 and analysed for radioactivity
(0- 0) and adsorption at 280nm (0 0). Arrows indicate VO
and V,. Fractions were pooled as indicated. (b) Separation of
endothelial proteoglycans on DEAE-Sephacel. Crude endothelial
proteoheparan sulphate (HS I) and proteochondroitin sulphate
(PCS) from a Sepharose CL-4B chromatography (see a) were
chromatographed on DEAE-Sephacel (5 ml) in 0.1 M Tris/HCl,
0.1% (w/v) CHAPS (3-(cholamidopropyl)dimethylammonio)-1-
propanesulphonate), 7 M Urea, 1 mM PMSF, 1 mM EDTA, pH 7.2
to which a gradient of 0-1 M NaCl (50+50 ml) was added.
Fractions of 2.5 ml were collected and analysed for radioactivity
(0 0) and conductivity (---, given as M NaCI). Fractions were
pooled as indicated and investigated for their susceptibility to
heparinase and chondroitinase AC. The pooled fractions of HS I
and PCS were contaminated with each other by <22%. Further
purification involved CsCl density gradient centrifugation (data
not shown) which yielded proteoglycan preparations that were
homogenous according to the criteria published elsewhere (Keller
& Furthmayr, 1986; Keller et al., 1987).
tion, the invasion process may also be more effective in areas
where the endothelial cell layer is injured or disturbed in its
confluency, so that subendothelial ECM is readily exposed
to degradative enzymes of tumour cells.
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Figure 2 Chromatographic analysis of proteoglycans after
incubation with highly- and low-metastatic tumour cells. In a
typical experiment, wells of a microtitre plate were coated with
-200ng endothelial HS I, endothelial PCS or a basement mem-
brane proteoheparan sulphate (HR9-PHS) at 20°C for 3 h under
sterile conditions. The microtitre plates were washed thoroughly
with phosphate buffered saline (PBS)+2% (v/v) bovine serum.
The specific (35S)-radioactivity of all three (35S)-labelled proteo-
glycans was 1.5 x I07 cpmmg-1 repeating unit disaccharide, as
determined from the amount of HexN in the hydrolysate. PCS
was chromatographed on Sepharose CL-6B before (a, ) and
after alkali digestion (a, ) or degradation with chondroitinase
AC (a, ---), after incubation with Eb cells (d), with ESb-MP
cells (g) and with ESb cells (j). HSI was chromatographed on
Sepharose CL-6B before (b, ) and after alkali digestion
(b, )) or degradation with heparinase (b, ---), after incuba-
tion with Eb cells (e), with ESb-MP cells (h) and with ESb cells
(k). HR9-PHS was chromatographed on Sepharose CL-6B before
(c, ) and after digestion with alkali (c, -) or heparinase
(c, ), after incubation with Eb cells (f), with ESb-MP cells (i)
and after incubation with ESb cells (1).
All incubations were carried out for 24h in RPMI 1640+100%
(v/v) foetal calf serum at 37°C in an 5% CO2 atmosphere (200M1
cell suspension, cell density: 1 x 105 cellsml-'). Viability of the
tumour cells was not affected by incubation on the proteoglycan-
coated wells. After incubation, the cell suspension was removed,
centrifuged at 1,000g for 5 min and the supernatant combined
with a 501M 0.1M Tris/HCl, 2% (w/v) SDS, 7M urea, pH7.2
extract of the material remaining attached to the microtitre well.
The combined solutions were precipitated in 80% (v/v) ethanol,
solubilized in 0.13M Tris/HCl, 0.1%0 (w/v) SDS, 1 mM PMSF,
1 mM EDTA, pH 7.2 and chromatographed on Sepharose CL-6B
(0.5 x 50cm) in the same buffer. Radioactivity could not be
detected in the supernatants after precipitation in ethanol. Frac-
tions of 200p1 were collected at 1 mlh-1 and analysed for
radioactivity. Arrows indicate V0 and V,. Alkali digestions and
degradation with Chondroitinase AC or Heparinase were carried
out as described (Keller & Furthmayr, 1986; Keller et al., 1987).
Endoglycosidases may also be involved in the organotro-
pism of metastatic tumour cells. For instance, Nakajima et
al. (1983) reported for the B16 melanoma system that
variants colonising in ovaries showed lower activity in
degrading purified lung heparan sulphate than those variants
colonising in the lung. In conclusion, the results reported
here, together with observations made in other tumour
systems, underline the necessity to study the substrate speci-
ficity of tumour-associated endoglycosidases in more detail
for better understanding the metastatic process.
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Figure 3 Kinetics of ESb-endoglycosidase activity on HR9-PHS.
(35S)-labelled HR9-PHS coated microtitre wells were incubated
with ESb cells for 10min (a), 20min (b), 30min (c), 60min (d),
and 120min (e). The incubations and the chromatographies were
performed as described in Figure 2. Arrows indicate V0 and V,.
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